Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheumatology Drug Updates

Michele D. Kaufman, PharmD, BSc, RPh  |  Issue: September 2013  |  

Michele Kaufman is a freelance medical writer based in New York City, a pharmacist at New York Presbyterian–Lower Manhattan Hospital, and adjunct faculty at Touro College of Pharmacy.

References

  1. FDA advisor panel votes against new use of AbbVie’s Humira. Published July 23, 2013. www.reuters.com/article/2013/07/23/us-fda-arthritis-humira-idUSBRE96M0PV20130723. Accessed August 1, 2013.
  2. Dearment A. FDA approves Zubsolv for the maintenance treatment of opioid dependence. Published July 4, 2013. www.orexo.com/en/Investor-Relations/Press-releases/ ?guid=788294. Accessed August 1, 2013.
  3. FDA panel narrowly backs new use of UCB’s arthritis drug. Published July 23, 2013. www.reuters.com/article/2013/07/23/us-ucb-fda-idUSBRE96M11S20130723. Accessed July 24, 2013.
  4. Dennis M. Novartis’ Sandoz unit starts late-stage trial of biosimilar version of Amgen’s Enbrel. Published June 24, 2013. www.firstwordpharma.com/node/1111986#axzz2ar2peBl0. Accessed June 24, 2013.
  5. Walsh N. IV Simponi Aria OK’d for arthritis. Published July 19, 2013. www.medpagetoday.com/Rheumatology/Arthritis/40580. Accessed August 1, 2013.
  6. DeArment A. Actavis’ generic version of Opana ER wins FDA approval. Published July 12, 2013. http://ir.actavis.com/phoenix.zhtml?c=65778&p=irol-newsArticle&ID=1837442. Accessed August 1, 2013.
  7. Fischer A. Brisdelle (paroxetine) approval for menopausal vasomotor symptoms (hot flashes) and warning update on concomitant use with tamoxifen. Published June 28, 2013. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm359030.htm. Accessed August 1, 2013.
  8. US FDA accepts Iroko Pharma’s NDA filing of lower dose submicron indomethacin to treat mild to moderate acute pain in adults. Published July 18, 2013. www.pharmabiz.com/NewsDetails.aspx?aid=76546&sid=2. Accessed August 1, 2013.
  9. FDA Drug Safety Communication: FDA warns of rare but serious skin reactions with the pain reliever/fever reducer acetaminophen. Published August 1, 2013. www.fda.gov/downloads/Drugs/DrugSafety/UCM363052.pdf. Accessed August 1, 2013.
  10. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. Published July 26, 2013. www.fda.gov/Drugs/DrugSafety/ucm362415.htm. Accessed July 26, 2013.
  11. Actemra (tocilizumab) injection: Safety label changes. Published April 2013. www.fda.gov/Safety/MedWatch/SafetyInformation/ucm352022.htm. Accessed August 1, 2013.
  12. Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med. 2013;173:754-761.

Related Articles